Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · IEX Real-Time Price · USD
1.990
-0.100 (-4.78%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Lexicon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for LXRX stock has a target of 10, which predicts an increase of 402.51% from the current stock price of 1.99.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for LXRX stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +402.51% | Jul 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +402.51% | Jun 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +402.51% | Jun 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +402.51% | Jun 17, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 3, 2024 |
Financial Forecast
Revenue This Year
24.60M
from 1.20M
Increased by 1,942.86%
Revenue Next Year
85.37M
from 24.60M
Increased by 247.08%
EPS This Year
-0.78
from -0.80
EPS Next Year
-0.70
from -0.78
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.1M | 108.2M | 248.0M | 477.8M | 689.0M |
| Avg | 24.6M | 85.4M | 181.7M | 298.3M | 619.3M |
| Low | 13.7M | 51.1M | 138.9M | 116.7M | 547.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3,399.8% | 340.1% | 190.6% | 163.0% | 131.0% |
| Avg | 1,942.9% | 247.1% | 112.8% | 64.2% | 107.6% |
| Low | 1,039.5% | 107.6% | 62.7% | -35.7% | 83.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.65 | -0.64 | -0.13 | 0.74 | 1.42 |
| Avg | -0.78 | -0.70 | -0.38 | 0.02 | 1.38 |
| Low | -0.86 | -0.74 | -0.57 | -0.69 | 1.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 5,864.4% |
| Avg | - | - | - | - | 5,694.0% |
| Low | - | - | - | - | 5,466.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.